What is the clinical evidence from this study?

Study design: Other. Population: Normal physiology (animal model) (n=29). Intervention: Atrial natriuretic factor (ANF) vs. Control period (baseline). Primary outcome: Glomerular filtration rate (GFR) (p=<0.005).

October 1, 1986Proceedings of the National Academy of Sciences

In vivo evidence that cGMP is the second messenger for atrial natriuretic factor.

View Full Paper

Ask AI

Bookmark

Key result

Atrial natriuretic factor increased glomerular filtration rate by 45% and induced a >5-fold increase in Bowman's space cGMP concentration, indicating cGMP is its second messenger in vivo.

Population

In vivo model (species not specified in abstract) for studying renal hemodynamic action

Comparison

Administration of atrial natriuretic factor and… vs Controls and dibutyryl cAMP

Design

Preclinical

Authors

CHChou‐Long HuangUniversity of Iowa HIHarlan E. IvesUniversity of California, San Francisco MCMartin G. CoganStanford University

Discussion

Member takes

Implication

Animal data support cGMP mediation of ANF renal effects; human relevance remains untested.

Structured PICO

Population

In vivo model (species not specified in abstract) for studying renal hemodynamic action

Intervention

Administration of atrial natriuretic factor (ANF) and intrarenal arterial infusion of dibutyryl cGMP (10 to 1000 microM)

Comparator

Controls (for ANF) and dibutyryl cAMP (for dibutyryl cGMP)

Outcome

Glomerular filtration rate (GFR) and cGMP concentration in systemic artery, renal vein, urine, Bowman's space, and end-proximal tubulesurrogate

Main Result

Absolute Event Rate: 1.6% vs 1.1%

p-value: p=<0.005

The study demonstrates in vivo that ANF markedly stimulates glomerular production of cGMP, which acts as the second messenger mediating its effect of increasing glomerular filtration rate.

Limitations

Extracellular application of cGMP analog should be interpreted cautiously due to limited understanding of physiological cellular concentration.
The 0.1-1 mM Bt2cGMP concentrations used may be unphysiological.
Lack of explicit examination of endothelial cells as a source of cGMP production.

Cite This Study

Huang et al. (1986) studied Normal physiology (animal model) (n=29). Atrial natriuretic factor (ANF) vs. Control period (baseline) was evaluated on Glomerular filtration rate (GFR) (p=<0.005). Atrial natriuretic factor increased glomerular filtration rate by 45% and induced a >5-fold increase in Bowman's space cGMP concentration, indicating cGMP is its second messenger in vivo.

synapsesocial.com/papers/6a0fab722badbc352afe84f6 https://doi.org/10.1073/pnas.83.20.8015

View Full Paper

Ask AI

Bookmark

October 1, 1986Proceedings of the National Academy of Sciences

In vivo evidence that cGMP is the second messenger for atrial natriuretic factor.

View Full Paper

Ask AI

Bookmark

Key result

Atrial natriuretic factor increased glomerular filtration rate by 45% and induced a >5-fold increase in Bowman's space cGMP concentration, indicating cGMP is its second messenger in vivo.

Population

In vivo model (species not specified in abstract) for studying renal hemodynamic action

Comparison

Administration of atrial natriuretic factor and… vs Controls and dibutyryl cAMP

Design

Preclinical

Authors

CHChou‐Long HuangUniversity of Iowa HIHarlan E. IvesUniversity of California, San Francisco MCMartin G. CoganStanford University

Discussion

Member takes

Implication

Animal data support cGMP mediation of ANF renal effects; human relevance remains untested.

Structured PICO

Population

In vivo model (species not specified in abstract) for studying renal hemodynamic action

Intervention

Administration of atrial natriuretic factor (ANF) and intrarenal arterial infusion of dibutyryl cGMP (10 to 1000 microM)

Comparator

Controls (for ANF) and dibutyryl cAMP (for dibutyryl cGMP)

Outcome

Glomerular filtration rate (GFR) and cGMP concentration in systemic artery, renal vein, urine, Bowman's space, and end-proximal tubulesurrogate

Main Result

Absolute Event Rate: 1.6% vs 1.1%

p-value: p=<0.005

The study demonstrates in vivo that ANF markedly stimulates glomerular production of cGMP, which acts as the second messenger mediating its effect of increasing glomerular filtration rate.

Limitations

Extracellular application of cGMP analog should be interpreted cautiously due to limited understanding of physiological cellular concentration.
The 0.1-1 mM Bt2cGMP concentrations used may be unphysiological.
Lack of explicit examination of endothelial cells as a source of cGMP production.

Cite This Study

synapsesocial.com/papers/6a0fab722badbc352afe84f6 https://doi.org/10.1073/pnas.83.20.8015

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark